Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting
The details of the presentation are as follows:
- Title: JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata
- Date and Time:
Saturday, March 2, 2019, 1:00 - 4:00 p.m.
- Session: S034:
Late-Breaking Research: Clinical Trials
- Room: Ballroom A
- Abstract Number: 11291
CTP-543 was discovered by applying Concert's deuterium chemistry
technology to modify ruxolitinib, a drug which inhibits Janus kinases 1
and 2 (JAK1 and JAK2) and is commercially available under the name
Jakafi® in the United States for the treatment of certain blood
disorders. Deuterium modification of ruxolitinib was found to alter its
human pharmacokinetics in ways which may enhance its use as a treatment
for alopecia areata.
About Alopecia Areata
Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40. It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.
Following the FDA’s Patient-Focused Drug Development meeting held in
Cautionary Note on Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our expectations for
clinical development of CTP-543, and other statements containing the
words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would,” and similar expressions, constitute
forward-looking statements within the meaning of
1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.